Latest:
Dr. Gertz on the Outlook for Waldenstrom Macroglobulinemia
Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Morie Gertz, MD
Latest:
Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial
SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.
Morris Sherman, MD, PhD
Latest:
Dr. Sherman on Screening Obstacles in Liver Cancer
Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the issues oncologists face with screening patients for hepatocellular carcinoma (HCC) in an interview during the 10th International Liver Cancer Association (ILCA) Annual Conference.
Moshe Ornstein, MD
Latest:
Postimmunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.
Motzer RJ, Escudier B, Oudard S, et al.
Latest:
Everolimus Improves Progression-Free Survival in Patients with Previously Treated Metastatic RCC
A subgroup analysis of a randomized trial showed that patients with previously treated metastatic renal cell carcinoma had significant improvement in progression-free survival when they received everolimus.
MPH, Kristine Kokeny, MD
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations
Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate
cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Mrinal Patnaik, MBBS
Latest:
Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia
Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.
Mrinal S. Patnaik, MBBS
Latest:
Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms
Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.
Murray Korc, MD
Latest:
Combination Therapies Explored in Pancreatic Cancer Subgroups
To address the unmet need
for better diagnostic and
therapeutic modalities
in pancreatic cancer, investigators
at the Indiana University
School of Medicine have
established the Pancreatic Cancer
Signature Center at the Indiana
University Melvin and Bren
Simon Cancer Center.
N. Patrik Brodin, PhD
Latest:
Montefiore Study May Help Establish Patient Criteria for Proton Therapy
In an effort to build more sophisticated protocols that keep QoL and cost questions at the forefront, Montefiore Einstein Center for Cancer Care and
Albert Einstein College of Medicine’s Institute for Onco-Physics created a mathematical model to identify the optimal candidates for proton therapy, the most modern form of radiation therapy for patients with head and neck cancers.